AMED Valuation

Amedisys Inc

Add to Watchlist

Advanced Chart

97.940

+0.11(0.112%)1D

Overview
Forecast
Valuation
Earnings

AMED Relative Valuation

AMED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMED is overvalued; if below, it's undervalued.

Historical Valuation

Amedisys Inc (AMED) is now in the Undervalued zone, suggesting that its current forward PE ratio of 20.19 is considered Undervalued compared with the five-year average of 26.62. The fair price of Amedisys Inc (AMED) is between 109.06 to 185.91 according to relative valuation methord. Compared to the current price of 97.94 USD , Amedisys Inc is Undervalued By 10.2%.

Relative Value

Fair Zone

109.06-185.91

Current Price：97.94

10.2%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.68

P/B

Median3y

2.83

Median5y

4.98

6.84

FCF Yield

Median3y

4.46

Median5y

4.22

Competitors Valuation Multiple

The average P/S ratio for AMED's competitors is 1.96, providing a benchmark for relative valuation. Amedisys Inc Corp (AMED) exhibits a P/S ratio of 1.29, which is -34.08% above the industry average. Given its robust revenue growth of 4.09%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap